Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2024 14:30 ET | Source: Kamari Pharma

Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology

Phase 1b clinical trial of KM-001 demonstrated favorable safety profile and high responder rate of 87% in patients with palmoplantar keratoderma and pachyonychia congenita In vitro and in vivo...